Formulation And Evaluation Of Mouth Dissolving Tablets Of Celecoxib.

This research focused on the development and assessment of Lornoxicam Fast Disintegrating Tablets (FDTs), intended to deliver a faster onset of therapeutic action, improved bioavailability, and better patient adherence-especially for those who experience difficulty swallowing conventional tablets.Lornoxicam, a nonsteroidal anti-inflammatory drug (NSAID) known for its strong analgesic and anti-inflammatory effects, was chosen as the active pharmaceutical ingredient.The FDTs were manufactured using the direct compression technique, which is recognized for being both cost-effective and suitable for large-scale production.A range of excipients-including microcrystalline cellulose, crospovidone, sodium starch glycolate, and magnesium stearate-were incorporated to enhance the formulation's disintegration rate, flow characteristics, and compressibility.Pre-compression evaluations such as bulk density, tapped density, Carr's index, angle of repose, and moisture content were conducted to assess the blend's suitability for tablet formation.These studies confirmed acceptable flow and compressibility properties.Post-compression tests, including hardness, friability, disintegration time, and in vitro drug release, revealed that the developed tablets met the essential requirements for FDTs.The tablets disintegrated quickly in the presence of saliva, enabling rapid drug release.Overall, the formulated Lornoxicam FDTs demonstrated desirable characteristics in terms of mechanical strength, rapid disintegration, effective dissolution, and stability.Additionally, compatibility studies such as Fourier Transform Infrared Spectroscopy (FTIR) and in vitro dissolution of solid dispersions were employed to support the formulation's efficacy.